📋 Tender Overview
Contract awarded for Centralized framework agreement for 24 months for the supply of medicines xiii/2024 { "detected_language": "romanian", "translated_text": "lot-0039, title: epipen type combinations 300 mcg meda pharma ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0040, title: erdomed type combinations ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0068, title: lornoxicam 8 mg/2 ml type combinations ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0073, title: meloxicam rompharm 15 mg/1.5 ml type combinations ®, movalis ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0075, title: mirzaten® 30 mg, valdren 30 mg type combinations or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0077, title: algifen ® type combinations or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0080, title: avelox 400 mg ®, moflaxa ® or equivalent type combinations, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0084, title: vimovo 500 mg/20 mg ® type combinations or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0099, title: janumet 50 mg/1000 mg type combinations or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0107, title: teotard 200 mg type combinations or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0108, title: teotard 350 mg type combinations or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0115, title: tobrom ® type combinations or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities both under the framework agreement and under the subsequent estimated value excluding vat: 3830046.60 ron.Centralized framework agreement for 24 months for the supply of medicines xiii/2024
